 
 
Official Title:  The Effect of Bone -void Filler on Anterior Knee Pain Following ACL 
Reconstruction With Bone -Patellar Tendon Bone Autograft   
NCT Number : [STUDY_ID_REMOVED]  
Study Number:  20-[ZIP_CODE]  
Document Type:   Study Protocol and Statistical Analysis Plan  
Date of the 
Document:  • August 18, 2020  
 
 
  Page i 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_727753] OF BONE-VOID FILLER ON ANTERIOR KNEE PAIN FOLLOWING BPTB  
AUTOGRAFT ACL  RECONSTRUCTION  
.   
 
Principal Investigator:  
  
[INVESTIGATOR_553745], MD  
NYU Langone Orthopedic Hospi[INVESTIGATOR_553746]  
[ADDRESS_727754]  
[LOCATION_001], NY [ZIP_CODE] 
 
 
Additional  Investigator s: 
  
Alexander Hoberman, MD  
Department of Orthopedic Surgery  
[ADDRESS_727755], [LOCATION_001], NY [ZIP_CODE] 
[EMAIL_10539]  
[PHONE_11523]  
 
Michael J Alaia, MD  
Department of Orthopedic Surgery  
[ADDRESS_727756], [LOCATION_001], NY [ZIP_CODE]  
[EMAIL_10540]  Kirk A Campbell, MD  
Department of Orthopedic Surgery  
[ADDRESS_727757], [LOCATION_001], NY [ZIP_CODE]  
[EMAIL_10541]  Guillem Gonzal ez-Lomas, MD  
Department of Orthopedic Surgery  
[ADDRESS_727758], [LOCATION_001], NY [ZIP_CODE]  
Guillem.gonzalez -[EMAIL_10542] 
 
Laith M. Jazrawi, MD  Department of Orthopedic Surgery  
[ADDRESS_727759], [LOCATION_001], NY [ZIP_CODE]  
laith.jazrawi @nyulangone.org  
 
 
NYULH  Study Number:  
 s20-[ZIP_CODE] 
 
Funding Sponsor:   
 
 
ClinicalTrials.gov 
Number                 
  Page ii 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  
  
 
Initial version:  8/4/2020 
Amended:  [date]  
Amended:  [date]  
 
Study number:  s20-[ZIP_CODE]   Page iii 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019   
Statement of Compliance  
 
This study will be conducted in accordance with the Code of Federal Regulations on the Protection of 
Human Subjects (45 CFR Part 46), 21 CFR Parts 50, 56, 312, and 812 as applicable, any other applicable US government research regulations, and institutional research policies and procedures. The International Conference on Harmonisation (“ICH”) Guideline for Good Clinical Practice (“GCP”) (sometimes referred to as “ICH- GCP” or “E6”) will be applied only to the extent that it is compatible with FDA and DHHS r egulations.  
The Principal Investigator [INVESTIGATOR_7433], or changes to the protocol will take place without prior agreement from the sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel involved in the conduct of this study have completed Human Subjects Protection Training.  
  
Study number:  s20-[ZIP_CODE]   Page iv 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_727760] OF ABBREVIATIONS .................................................................................................................. VII 
PROTOCOL SUMMARY  ............................................................... ERROR! BOOKMARK NOT DEFINED.  
SCHEMATIC OF STUDY DESIGN  ................................................ ERROR! BOOKMARK NOT DEFINED.  
1 KEY ROLES  ......................................................................... ERROR! BOOKMARK NOT DEFINED.  
2 INTRODUCTION, BACKGROUND INFORMATION AND  SCIENTIFIC RATIONAL E ...................... 9 
2.1 BACKGROUND INFORMATION AND RELEVANT LITERATURE  ............................................................. 9 
2.2 NAME [CONTACT_33914]  ............ ERROR ! BOOKMARK NOT DEFINED . 
2.2.1  Preclinical Data  ..................................................................... Error! Bookmark not defined.  
2.2.2  Clinical Data to Date ............................................................. Error! Bookmark not defined.  
2.2.3  Dose Rationale (if applicable)  ............................................... Error! Bookmark not define d. 
2.3 RATIONALE  ............................................................................................................................. 10 
2.4 POTENTIAL RISKS & BENEFITS  ................................................................................................. 10 
2.4.1  Known Potential Risks  ...................................................................................................... 10 
2.4.2  Known Potential Benefits  .................................................................................................. 10 
3 OBJECTIVES AND PURPO SE ..................................................................................................... 10 
3.1 PRIMARY OBJECTIVE  ............................................................................................................... 10 
3.2 SECONDARY OBJECTIVES (IF APPLICABLE ) ................................................................................. 11 
4 STUDY DESIGN AND ENDPOINTS  ............................................................................................. 11 
4.1 DESCRIPTION OF STUDY DESIGN  .............................................................................................. 11 
4.2 STUDY ENDPOINTS .................................................................................................................. 11 
4.2.1  Primary Study Endpoints  .................................................................................................. 11 
4.2.2  Secondary Study Endpoints  .............................................................................................. 11 
4.2.3  Exploratory Endpoints  ....................................................................................................... 11 
5 STUDY ENROLLMENT AND  WITHDRAWAL  ............................................................................... 11 
5.1 INCLUSION CRITERIA  ............................................................................................................... 11 
5.2 EXCLUSION CRITERIA  .............................................................................................................. 11 
5.3 VULNERABLE POPULATIONS  ..................................................................................................... 12 
5.4 STRATEGIES FOR RECRUITMENT AND RETENTION  ....................................................................... 12 
5.5 DURATION OF STUDY PARTICIPATION  ........................................................................................ 12 
5.6 TOTAL NUMBER OF PARTICIPANTS AND SITES ............................................................................ 12 
5.7 PARTICIPANT WITHDRAWAL OR TERMINATION  ............................................................................ 12 
5.7.1  Reasons for Withdrawal or  Termination  ............................................................................ 12 
5.7.2  Handling of Participant Withdrawals or Termination ........................................................... 13 
5.8 PREMATURE TERMINATION OR SUSPENSION OF STUDY  ................. ERROR ! BOOKMARK NOT DEFINED . 
6 STUDY AGENT (STUDY DRUG, DEVICE, BIOLOGI C, VACCINE ETC.) AND/OR PROCEDURAL 
INTERVENTION .................................................................................................................................... 13 
6.1 STUDY AGENT (S) AND CONTROL DESCRIPTION  ............................ ERROR ! BOOKMARK NOT DEFINED . 
6.1.1  Acquisition  ............................................................................ Error! Bookmark not defined.  
6.1.2  Formulation, Appearance, Packaging, and Labeling  .............. Error! Bookmark not defined.  
6.1.[ADDRESS_727761] Storage and Stability  ................................................ Error! Bookmark not defined.  
6.1.4  Preparation  ........................................................................... Error! Bookmark not defined.  
6.1.5  Dosing and Administration .................................................... Error! Bookmark not defined.  
6.1.6  Route of Administration ......................................................... Error! Boo kmark not defined.  
6.1.7  Starting Dose and Dose Escalation Schedule  ....................... Error! Bookmark not defined.  
6.1.8  Dose Adjustments/Modifications/Delays  ................................ Error! Bookmark not defined.  
Study number:  s20-[ZIP_CODE]   Page v 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  6.1.9  Duration of Therapy  .............................................................. Error! Bookmark not defined.  
6.1.10  Tracking of Dose  .............................................................. Error! Bookmark not defined.  
6.1.11  Device Specific Considerations  ..................................................................................... 13 
6.2 STUDY AGENT ACCOUNTABILITY PROCEDURES  .......................................................................... 13 
6.3 STUDY BEHAVIORAL OR SOCIAL INTERVENTION (S) ........................ ERROR ! BOOKMARK NOT DEFINED . 
6.3.1  Administration of Intervention  ............................................................................................ 13 
6.3.2  Procedures for Training Interventionalists and Monitoring Intervention Fidelity  ............ Error! 
Bookmark not defined.  
6.3.[ADDRESS_727762] Compliance with Study Intervention  .............................................. 13 
6.4 STUDY PROCEDURAL INTERVENTI ON(S) DESCRIPTION  ................................................................ 13 
6.4.1  Administration of Procedural Intervention  .......................................................................... 13 
6.4.2  Procedures for Training of Clinicians on Procedural Intervention Error! Bookmark not 
defined.  
6.4.3  Assessment of Clinician and/or Participant Compliance with Study Procedural Intervention
 Error! Bookmark not defined.  
7 STUDY PROCEDURES AND  SCHEDULE  ................................................................................... 14 
7.1 STUDY PROCEDURES /EVALUATIONS  ......................................................................................... [ADDRESS_727763] of Care Study Procedures  .................................................................................. 14 
7.2 LABORATORY PROCEDURES /EVALUATIONS  ................................................................................ 14 
7.2.1  Clinical Laboratory Evaluations  ............................................. Error! Bookmark not defined.  
7.2.2  Other Assays or Procedures  ................................................. Error! Bookmark not defined.  
7.2.3  Specimen Preparation, Handling, and Storage  ...................... Error! Bookmark not defined.  
7.2.4  Specimen Shipment  .............................................................. Error! Bookmark not defined.  
7.3 STUDY SCHEDULE  ................................................................................................................... 14 
7.3.1  Screening  ......................................................................................................................... 14 
7.3.2  Enrollment/Baseline  .......................................................................................................... 14 
7.3.3  Intermediate Visits  ............................................................................................................ 15 
7.3.4  Final Study Visit  ................................................................................................................ 15 
7.3.5  Withdrawal/Early Termination Visit  ........................................ Error! Bookmark not defined.  
7.3.6  Unscheduled Visit  ............................................................................................................. 16 
7.4 CONCOMITANT MEDICATIONS , TREATMENTS , AND PROCEDURES  .... ERROR ! BOOKMARK NOT DEFINED . 
7.5 JUSTIFICATION FOR SENSITIVE PROCEDURES  ............................... ERROR ! BOOKMARK NOT DEFINED . 
7.5.1  Precautionary Medications, Treatments, and Pr ocedures  ...... Error! Bookmark not defined.  
7.6 PROHIBITED MEDICATIONS , TREATMENTS , AND PROCEDURES  ....... ERROR ! BOOKM ARK NOT DEFINED . 
7.7 PROPHYLACTIC MEDICATIONS , TREATMENTS , AND PROCEDURES  ... ERROR ! BOOKMARK NOT DEFINED . 
7.8 RESCUE MEDICATIONS , TREATMENTS , AND PROCEDURES  ............. ERROR ! BOOKMARK NOT DEFINED . 
7.9 PARTICIPANT ACCESS TO STUDY AGENT AT STUDY CLOSURE  ........ ERROR ! BOOKMARK NOT DEFINED . 
8 ASSESSMENT OF SAFETY  ......................................................................................................... 16 
8.1 SPECIFICATION OF SAFETY PARAMETERS  .................................................................................. 16 
8.1.1  Definition of Adverse Events (AE)  ..................................................................................... 16 
8.1.2  Definition of Serious Adverse Events (SAE)  ...................................................................... 16 
8.1.3  Definition of Unanticipated Problems (UP)  ........................................................................ 16 
8.2 CLASSIFICATION OF AN ADVERSE EVENT  ................................................................................... 17 
8.2.1  Severity of Event  .............................................................................................................. 17 
8.2.2  Relationship to Study Agent  .............................................................................................. 17 
8.2.3  Expectedness  ....................................................................... Error! Bookmark not defined.  
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UPERROR ! BOOKMARK NOT 
DEFINED . 
8.4 REPORTING PROCEDURES – NOTIFYING THE IRB ....................................................................... 17 
8.4.1  Adverse Event Reporting  .................................................................................................. 17 
8.4.2  Serious Adverse Event Reporting  ......................................... Error! Bookmark not defined.  
8.4.3  Unanticipated Problem Reporting ...................................................................................... 17 
8.4.4  Reporting of Pregnancy  .................................................................................................... 18 
8.5 REPORTING PROCEDURES – NOTIFYING THE STUDY SPONSOR  ...... ERROR ! BOOKMARK NOT DEFINED . 
Study number:  s20-[ZIP_CODE]   Page vi 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019  8.7 REPORTING PROCEDURES – PARTICIPATING INVESTIGATORS  ........ ERROR ! BOOKMARK NOT DEFINED . 
8.8 STUDY HALTING RULES  ........................................................................................................... 18 
8.9 SAFETY OVERSIGHT  ................................................................................................................ 18 
9 CLINICAL MONITORING  ............................................................................................................. 18 
10 STATISTICAL CONSIDERATIONS  .............................................................................................. 19 
10.1  STATISTICAL AND ANALYTICAL PLANS (SAP)  ................................ ERROR ! BOOKMARK NOT DEFINED . 
10.2  STATISTICAL HYPOTHESES ....................................................................................................... 19 
10.3  ANALYSIS DATASETS  ............................................................................................................... 19 
10.4  DESCRIPTION OF STATISTICAL METHODS  ................................................................................... 19 
10.4.1  General Approach  ........................................................................................................ 19 
10.4.2  Analysis of the Primary Efficacy Endpoint(s)  ................................................................. 19 
10.4.3  Analysis of the Secondary Endpoint(s)  .......................................................................... 19 
10.4.4  Safety Analyses  ................................................................ Error! Bookmark not defined.  
10.4.5  Adherence and Retention Analyses  .............................................................................. 19 
10.4.6  Baseline Descriptive Statistics  ...................................................................................... 19 
10.4.7  Planned Interim Analysis  .............................................................................................. 19 
10.4.8  Additional Sub- Group Analyses  .................................................................................... 20 
10.4.9  Multiple Comparison/Multiplicity  .................................................................................... 20 
10.4.10  Tabulation of I ndividual Response Data  ........................................................................ 20 
10.4.11  Exploratory Analyses  .................................................................................................... 20 
10.5  SAMPLE SIZE .......................................................................................................................... 20 
10.6  MEASURES TO MINIMIZE BIAS ..................................................... ERROR ! BOOKMARK NOT DEFINED . 
10.6.1  Enrollment/R andomization/Masking Procedures  ............... Error! Bookmark not defined.  
10.6.2  Evaluation of Success of Blinding  ..................................... Error! Bookmark not defined.  
10.6.3  Breaking the Study Blind/Participant Code  ........................ Error! Bookmark not defined.  
11 SOURCE DOCUMENTS AND  ACCESS TO SOURCE DA TA/DOCUMENTS ................................ 20 
12 QUALITY ASSURANCE AND QUALITY CONTRO L .................................................................... 21 
13 ETHICS/PROTECTION OF  HUMAN SUBJECTS  .......................................................................... [ADDRESS_727764]  ................................................................................................ 21 
13.3  INFORMED CONSENT PROCESS  ................................................................................................ 21 
13.3.1  Consent/Assent and Other Informational Documents Provided to Participants  .............. [ADDRESS_727765] KEEPI[INVESTIGATOR_1645]  ............................................................................... 22 
14.1  DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  ........................................................... 22 
14.2  STUDY RECORDS RETENTION  .................................................................................................. 23 
14.3  PROTOCOL DEVIATIONS  ........................................................................................................... 23 
14.4  PUBLICATION AND DATA SHARING POLICY ................................... ERROR ! BOOKMARK NOT DE FINED . 
[ADDRESS_727766] POLICY  .............................................................................................. 23 
Study number:  s20-[ZIP_CODE]   Page vii 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: 11 January 2019   
  
 
 
 
     
 
     
 
    
 
     
 
     
 
    
 
     
 
     
 
  
 
Study number:  s20-[ZIP_CODE]   Page viii 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_110810]: [ADDRESS_727767] of Abbreviations  
 
 
AE Adverse Event/Adverse Experience  
CFR Code of Federal Regulations  
CRF Case Report Form  
CSOC  Clinical Study Oversight Committee  
DCC  Data Coordinating Center  
DHHS  Department of Health and Human Services  
DSMB  Data and Safety Monitoring Board  
FFR Federal Financial Report  
FWA  Federalwide Assurance  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
ICF Informed Consent Form  
ICH International Conference on Harmonisation  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_33891])  
NIH National Institutes  of Health  
OHRP  Office for Human Research Protections  
OHSR  Office of Human Subjects Research  
PI [INVESTIGATOR_251961]/Serious Adverse Experience  
SOP  Standard Operating Procedure  
US [LOCATION_002]  
 
 
Study number:  s20-[ZIP_CODE]   Page 9 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_553748]: 11 January 2019   
1 Introduction, Background Information and Scientific Rationale  
 
1.1 Background Information and Relevant Literature 
 
Anterior cruciate ligament (ACL) injuries are commonly seen and treated by [CONTACT_553749] 400,[ADDRESS_727768] the injured ACL in order to restore native knee biomechanics
1,2. There are many graft choices 
including bone- patellar -tendon- bone (BPTB), hamstring tendon or quadricep autograft as well as several 
different allografts that the surgeon may choose from. Each graft has specific properties that contribute to 
surgeon choice. Graft -specific complications exist as well which further aid in the choice of graft.[ADDRESS_727769] it over time. Calcium 
Study number:  s20-[ZIP_CODE]   Page 10 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_553748]: [ADDRESS_727770] compressive strength of synthetic bone grafts8. Calcium phosphate is 
commercially available and already used by [CONTACT_553750]- void after 
the BPTB autograft harvest7.  
 
Demineralized bone matrix (DBM) graft is another commonly used bone void filler used throughout orthopedic surgery. DBM has osteoinductive and osteoconductive properties that facility bony ingrowth. DBM is commonly used by [CONTACT_553751]
9.  
 
1.[ADDRESS_727771] 
practice.   
Potential  Risks & Benefits 
1.2.1  Known Potential Risks 
The differing materials used will not prolong or significantly extend the time of surgery.  
Possible adverse effects of using DBM  include, but are not limited to:  infection of soft tissue or 
bone, fever, deformity of the bone at the site of use, incomplete bone ingrowth, fracture of newly 
formed bone, hypercalcemia or transient hypercalcemia.  
Possible adverse effects of using calcium phosphate cement include, but are not limited to:  wound 
infection, wound dehiscence, fracture, loss of reduction, delayed or non -consolidation. While these 
risks are rare we will continue to monitor your condition to make sure these risks are minimized.  
However, use of these elements are all considered standard of practice and used by [CONTACT_553752], will not increase the level of risk for the patient beyond the normal surgery.  
1.2.[ADDRESS_727772] of  three different bone- void filler s 
(autogenous bone obtained from graft preparation and bone plug customization; autologous bone plus DBM; 
Study number:  s20-[ZIP_CODE]   Page 11 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_553748]: 11 January 2019  or autologous bone plus calcium phosphate cement)  on anterior knee pain following ACL reconstruction BPTB 
autograft . 
2.2 Secondary Objectives (if applicable)  
Secondary outcomes include patient reported quality of life and functional outcome measures, rate (if any) of 
patella fracture, r ate of r eturn to activity,  cost effectiveness and adverse events.  
[ADDRESS_727773]. 
The three cohorts will include 1) autogenous bone obtained from the BTBPB graft harvest 2) Autologous bone 
plus demineralized bone matrix (Allosync DBM Putty, Arthrex, naples, FL) and 3) autologous bone plus calcium 
phosphate cement (Quickset, Arthrex, Naples, FL).  
 
3.2 Study Endpoints  
3.2.1  Primary Study Endpoints  
Primary endpoint will be based on the following postoperative surveys: KOOS, Kujala , IKDC, VAS for pain,  
3.2.[ADDRESS_727774] meet all of the following criteria:  
• Patients undergoing ACLR with BPTB autograft  
• Skeletally mature (as defined by [CONTACT_553753])  
• At least 18 years of age  
• Willing and able to provide consent  
 
4.2  Exclusion Criteria  
An individual who meets any of the following criteria will be excluded from participation in this study:  
Study number:  s20-[ZIP_CODE]   Page 12 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_553748]: 11 January 2019  • knee with intact ACL  
• skeletally immature (as defined by [CONTACT_553754])  
• pregnant  
• less than 18 years of age  
• previous ACL repair or reconstruction 
• unable to speak english or perform informed consent  
• multiligamentous knee injury (two or more ligaments requiring surgical attention)  
• varus or valgus malalignment greater than 3 degrees  
 
4.3 Vulnerable Subjects  
No vulnerable subjects will be included in this study.  
 
4.4 Strategies for Recruitment and Retention  
No additional recruitment or retention strategies will be implemented.  
4.4.1  Use of DataCore/Epic Information for Recruitment Purposes  
 
This study will utilize EPIC to identify subjects  by  [CONTACT_553755].  Surgeons will present the study information to eligible patients 
at a preoperative office visit , whic h will provide subjects sufficient time to ask questions about the study and 
make a decision whether they would like to participate prior to their surgery . 
 
4.[ADDRESS_727775] size of 0.25 with 3 cohorts, a total of 159 patients are needed with 53 in each group. Assuming a 15% drop- out/lost to follow up rate, each group will enroll [ADDRESS_727776]. An investigator may 
terminate participation in the study if:  
 
• Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the participant  
 Commented [MR1]: Subjects should not be 
approached for study inclusion on the day of their 
surgery. Edit to indicate that subjects will be 
approached at a pre -operative visit.  
Study number:  s20-[ZIP_CODE]   Page 13 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_553748]: 11 January 2019  • The participant meets an exclusion criterion (either newly developed or not previously recognized) 
that precludes further study participation  
 
4.7.[ADDRESS_727777] of care postoperative visit schedule. Therefore, in the scenario 
that a patient withdraws from the study, they will still be seen and evaluated by [CONTACT_553756]. However, no additional data will be collected from 
subjects who withdraw from participating in this study.  
 
5 Study Agent  (Study drug, device, biologic, vaccine etc.) and/or 
Procedural Intervention  
The study agents in this study include Calcium phosphate cement (Quickset, Arthrex, Naples, FL) and Demineralized bone matrix (Allosync DBM Putty, Arthrex, naples, FL). The control group will receive 
autogenous  bone graft to fill the bone void.  
5.1.1  Device Specific Considerations  
Not applicable  
5.2 Study Agent Accountability Procedures  
The study agents are normally available (as part of standard of care) in the surgical suite. As per standard protocol, the study agents will be handled in a sterile manner, and the date of expi[INVESTIGATOR_553747]. If a product is opened but unused, it will be discarded.  
 
5.2.1  Administration of Intervention  
The use of the study agent will be done in- person, intraoperatively, by [CONTACT_11065]. Nearing the end of the 
procedure, either autologous bone graft, DBM, or  calcium phosphate cement will be used to fill in the site 
where the bone blocks were initially harvested (as part of the autograft). This intervention will only occur once, and will not be repeated.  
 
 
5.2.[ADDRESS_727778] Compliance with Study Interventi on 
N/A 
 
5.3 Study Procedural Intervention(s) Description 
The use of the study agent will be done intraoperatively, by [CONTACT_11065]. Nearing the end of the procedure, 
either autologous bone graft, DBM, or calcium phosphate cement will be used to fill in the site where bone blocks were initially harvested from the patella and tibia (as part of the autograft).  
 
5.3.1  Administration of Procedural Intervention  
Administration of the study agent during the procedure will be completed by [CONTACT_553757].  This is a one-
time procedural intervention that will not be repeated.  
 Commented [DP2]: Should this be autologous or 
autogenous?  
 
Ensure the cohorts and agents used in the study are 
consistent  throughout the protocol.  
Commented [EH3R2]: Autologous  
Commented [DP4R2]: Based on the background (p.9) 
and description of each cohort, the cohort that doesn’t 
receive an agent gets autogenous bone (e.g. Sections 
2.1 and 3.1 P.11)  
Study number:  s20-[ZIP_CODE]   Page 14 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_553748]: 11 January 2019  6 Study Procedures  and Schedule  
6.1 Study Procedures/Evaluations  
6.1.1  Study  Specific Procedures  
• Medical history (i.e. mechanism of injury, acuity of injury, co- morbidities , smoking status ) will be 
collected by [CONTACT_553758]  
• Physical exam (i.e. height, weight, range of motion, points of pain, ability to bear weight, and 
assessment of ligamentous laxity) will be performed during the first office visit  
• Radiographic images (which may include an X -ray, computed tomography scan, and/or magnetic 
resonance imaging scan, may be obtain as part of standard of care, independent of this study, to confirm the presence of a torn ACL and search for any concomitant pathology)  
• A discussion of if the results of any study specific procedures (e.g., radiographic or other imaging or laboratory evaluations) will be provided to participant.  
• If the patient is eligible for the study (i.e. meets inclusion/exclusion criteria), he/she will be informed of 
the study, and asked if they would like to participate (if yes, consent will be obtained by [CONTACT_553759] a study member)  
• Once consented, the following questionnaires  will be administered: VAS, KOOS, KUJALA IKDC  
• On day of surgery, surgeon will ensure patient is aware of their participation in the study, and will consent them for the procedure  
• Intraoperatively, when appropriate, the surgeon will use the appropriate graft (autologous bone graft, 
DBM, or calcium phosphate) based on the group to which the patient was randomized  
• The patient will return for post -operative vis its at the following intervals: [ADDRESS_727779] -operative visit, the patient will be asked to 
complete the same survey as completed preoperatively; if unable to obtain during the office visit , 
patients will be contact [CONTACT_553760] [ADDRESS_727780] of care.  
. 
6.2 Laboratory Procedures/Evaluations  
N/A 
6.3 Study Schedule  
 
6.3.1  Screening   
Screening (Day - 28 to - 1):  
• Obtain informed consent of potential participant verified by [CONTACT_553761] . 
• Review medical history to determine eligibil ity based on inclusion/exclusion criteria.  
• Review medications history to determine eligibility based on inclusion/exclusion criteria.  
6.3.2  Enrollment/ Baseline  
 
Enrollment/Baseline Visit (Visit 1, Day 0)  
• This is defined as the day of operation  
• Obtain informed consent of potential participant verified by [CONTACT_553762] 
(if consent was not already obtained during a pre- surgical visit)  
Study number:  s20-[ZIP_CODE]   Page 15 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_553748]: 11 January 2019  • Provide the patient with a key information sheet regarding the study  (if consent was not already 
obtained during a pre- surgical visit)  
• Verify inclusion/exclusion criteria.  
• Obtain demographic information, medical history, medication history, alcohol and tobacco use history.  
• Obtain preoperative questionnaire of primary and secondary outcomes  (VAS, KOOS, KUJALA IKDC)  
• Record vital signs, results of examinations, other assessments.  
• Administer the study treatment  intraoperatively (i.e. use of autologous bone graft, DBM, or calcium 
phosphate)  
6.3.3  Intermediate Visits  
[IP_ADDRESS]  Visit 2 
 
Visit 2 ( 1 week ± 4 days)   
• Record adverse events as reported by [CONTACT_145855].  
• Obtain questionnaire for primary and secondary outcomes  (VAS, KOOS, KUJALA IKDC)  
 
 
[IP_ADDRESS]  Visit 3  
 
Visit 3 (4- 6 week ± 2 weeks)   
• Record adverse events as reported by [CONTACT_145855].  
• Obtain questionnaire for primary and secondary outcomes  (VAS, KOOS, KUJALA IKDC)  
 
[IP_ADDRESS]  Visit 4  
 
Visit 4 ( 3 months  ± 3 weeks)   
• Record adverse events as reported by [CONTACT_145855].  
• Obtain questionnaire for primary and secondary outcomes  (VAS, KOOS, KUJALA IKDC)  
 
[IP_ADDRESS]  Visit 5  
 
Visit 4 (6 months ± 4 weeks)   
• Record adverse events as reported by [CONTACT_145855].  
• Obtain questionnaire for primary and secondary outcomes  (VAS, KOOS, KUJALA IKDC)  
 
[IP_ADDRESS]  Visit 6  
 
Visit 4 (9 months ± 4 weeks)   
• Record adverse events as reported by [CONTACT_145855].  
• Obtain questionnaire for primary and secondary outcomes  (VAS, KOOS, KUJALA IKDC)  
 
6.3.4  Final Study Visit  
 
Final Study Visit (12 months ± 4 weeks)   
• Record adverse events as reported by [CONTACT_145855].  
• Obtain questionnaire for primary and secondary outcomes  (VAS, KOOS, KUJALA IKDC)  
Study number:  s20-[ZIP_CODE]   Page 16 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_553748]: 11 January 2019   
6.3.5  Unscheduled Visit  
In the event of an unscheduled visit, no questionnaire will be administered.  
 
7 Assessment of Safety  
7.1 Specification of Safety Parameters  
7.1.1  Definition of Adverse Events (AE)  
 
An adverse event  (AE) is any symptom, sign, illness or experience that develops or worsens in severity 
during the course of  the study.  Intercurrent illnesses or injuries should be regarded as adverse events.  
Abnormal results of diagnostic procedures are considered to be adverse events if the abnormality:  
• results in study withdrawal  
• is associated with a serious adverse event  
• is associated with clinical signs or symptoms  
• leads to additional treatment or to further diagnostic tests  
• is considered by [CONTACT_1372] 
  
7.1.2  Definition of Serious Adverse Events (SAE)  
 
Serious Adverse Event  
Adverse events are classified as serious or non- serious.  A serious adverse event  is any AE that is:  
• fatal 
• life-threatening  
• requires or prolongs hospi[INVESTIGATOR_4408] 
• results in persistent or significant disability or incapacity  
• a congenital anomaly or birth defect  
• an important medical event  
 
Important medical events are those that may not be immediately life threatening, but are clearly of major clinical significance. They may jeopardize the subject, and may require intervention to prevent one of the 
other serious outcomes noted above. For example, drug overdose or abuse, a seizure that did not result in in-
patient hospi[INVESTIGATOR_059], or intensive treatment of bronchospasm in an emergency department would typi[INVESTIGATOR_15355].  
 All adverse events that do not meet any of the criteria for serious should be regarded as non -serious 
adverse events.  
 
7.1.3  Definition of Unanticipated Problems (UP)  
 
 
Unanticipated Problems Involving Risk to Subjects or Others  
Any incident, experience, or outcome that meets all of  the following criteria:  
• Unexpected in nature, severity, or frequency (i.e. not described in study -related documents such as 
the IRB -approved protocol or consent form, the investigators brochure, etc .) 
Study number:  s20-[ZIP_CODE]   Page 17 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_553748]: 11 January 2019  • R elated or possibly related to participation in the research (i.e. possibly related means there is a 
reasonable possibility that the incident experience, or outcome may have been caused by [CONTACT_9156])  
• Suggests that the research places subjects or others at greater risk of harm ( including physical, 
psychological, economic, or social harm).  
 
7.2 Classification of an Adverse Event  
7.2.1  Severity of Event  
 
For AEs not included in the protocol defined grading system, the following guidelines will be used to describe severity.  
 
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily activities.  
• Moderate – Events result in a low level of inconvenience or concern with the therapeutic measures. 
Moderate events may cause some interference with func tioning.  
• Severe – Events interrupt a participant’s usual daily activity and may require systemic drug therapy or 
other treatment. Severe events are usually potentially life- threatening or incapacitating.  
 
7.2.2  Relationship to Study Agent  
 The clinician’s assess ment of an AE's relationship to type of graft used (i.e. isolated autologous bone graft, 
DBM, calcium phosphate)  is part of the documentation process, but it is not a factor in determining what is or 
is not reported in the study. If there is any doubt as to whether a clinical observation is an AE, the event 
should be reported. All AEs must have their relationship to  study agent assessed. In a clinical trial, the study 
product must always be suspect. To help assess, the following guidelines are used.  
 
• Related – The AE is known to occur with the study agent, there is a reasonable possibility that the 
study agent caused the AE, or there is a temporal relationship between the study agent and event. 
Reasonable possibility means that there is evidence to suggest a causal relationship between the study agent and the AE.  
• Not Related  – There is not a reasonable possibility that the administration of the study agent caused 
the event, there is no temporal relationship between the study agent and event onset, or an alternate etiology has been established.  
 
7.3 Reporting Procedures  – Notifying the IRB   
7.3.1  Adverse Event Reporting 
Informati on about observed complications/adverse events will be documented in the electronic data collection 
system and/or on the paper CRFs, as appropriate. It will be the responsibility of the Principal Investigator [INVESTIGATOR_15359] (SAE) that occurs during the course of the outcomes data collection to the Institutional Review Board (IRB) within the timeframe specified by [CONTACT_15371].  
 
7.3.2  Unanticipated Problem Reporting 
 Incidents or events that meet the OHRP criteria for UPs require the creation and completion of an UP report 
form. It is the site investigator’s responsibility to report UPs to their IRB. The UP report will include the 
following information:  
 
Study number:  s20-[ZIP_CODE]   Page 18 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_553748]: 11 January 2019  • Protocol identifying information: protocol title and number, PI’s name, and the IRB project num ber; 
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome represents 
an UP;  
• A description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the UP.  
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
 
• UPs that are SAEs will be reported to the IRB within 72 hours  of the investigator becoming aware of 
the event.  
• Any other UP will be reported to the IRB and to the within 72 hours  of the investigator becoming aware 
of the problem.  
• All UPs should be reported to appropriate institutional officials (as required by [CONTACT_17347]’s written 
reporting procedures), the supporting agency head (or designee), and OHRP within<insert timeline in 
accordance with policy> of the IR’s receipt of the report of the problem from the investigator.  
 
7.3.3  Reporting of P regnancy  
Pregnant patients will not be included in thi s study.  
7.4 Study Halting Rules  
Administration of study agent will be halted when three grade 3 AEs determined to be “probably related” are 
reported.   
7.5 Safety Oversight  
It is the responsibility of the Principal Investigator [INVESTIGATOR_30900].  Th e data 
safety monitoring plan will include careful assessment and appropriate reporting of adverse events as noted 
above, as well as quarterly  review of enrollment , cumulative  data from the  patient -reported outcomes  (pain 
scores) , and adverse events . A yearly summary of adverse events and protocol deviations will be submitted 
to the IRB with the Continuation Submission in Research Navigator.  
[ADDRESS_727781] of the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with applicable regulatory 
requirement(s).  
 
• Monitoring for this study will be performed by [INVESTIGATOR_553745].  
• The monitoring will be on- site, early, for initial assessment and training, as well as throughout the 
study. This will be a quarterly review  to ensure that:  
o collection and storage of patient data was performed in a sensitive and secure manner, as 
defined in the informed consent form and protocol  
o All study activities were conducted with primary emphasis on patient care and well -being  
o There were no adverse events  
o The risk/benefit to patients has remained the same throughout the course of the study  
• This will be performed on a regular basis (every 3 months) 
 
Study number:  s20-[ZIP_CODE]   Page 19 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_553748]: 11 January 2019  9 Statistical Considerations  
9.1 Statistical Hypotheses  
There is no difference in level of anterior knee pain, as defined by [CONTACT_4676] -reported functional outcome scores, 
between the three treatment groups.  
 
9.2 Analysis Datasets  
There will be 3 groups for analysis: group 1 will be control, receiving autologous bone graft; group 2 will 
receive autologous bone graft along with DBM; group [ADDRESS_727782] deviations. To compare primary and secondary outcomes, an analysis of variance (ANOVA) will be performed, with a p- value of 0.05 set to determine statistical significance. Testing will be performed to 
determine whether sample distribution is normal; if not, non- parametric testing will be per formed.  
 
9.3.2  Analysis of the Primary Efficacy Endpoint(s)  
To compare primary  outcomes  (anterior knee pain), an analysis of variance (ANOVA) will be performed, with 
a p-value of 0.05 set to determine statistical significance. Testing will be performed to determine whether 
sample distribution is normal; if not, non- parametric testing will be performed.  Patients who do not complete at 
least 80% of follow -up visits will be considered lost to follow -up and will not be included in the analysis.  
 
9.3.3  Analysis of the  Secondary Endpoint(s)  
To compare secondary outcomes (functional outcomes scores, complication rates), an analysis of variance (ANOVA) will be performed, with a p- value of 0.05 set to determine statistical significance. For categorical 
variables, chi -squar ed testing will be performed. Testing will be performed to determine whether sample 
distribution is normal; if not, non- parametric testing will be performed. Patients who do not complete at least 
80% of follow -up visits will be considered lost to follow -up and will not be included in the analysis.  
  
9.3.[ADDRESS_727783] -operative visits at the following intervals: 1 week, 
4-6 weeks, 3 months, 6 months, 9 months, and 12 months.   
9.3.5  Baseline Descriptive Statistics  
Intervention groups will be compared on baseline characteristics, including demographics and laboratory 
measurements, using descriptive statistics. These characteristics will be compared at baseline (pre- operative 
time point) and at  final follow -up. 
9.3.6  Planned Interim Analysis  
Not applicable.  
 
Study number:  s20-[ZIP_CODE]   Page 20 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_553748]: 11 January 2019  9.3.7  Additional Sub -Group Analyses  
Not applicable,  
 
9.3.8  Multiple Comparison/Multiplicity  
Not applicable.  
9.3.[ADDRESS_727784] size of 0.25 with 3 cohorts, a total of 159 patients are needed with 53 in each group. 
Assuming a 15% drop- out/lost to follow up rate, each group will enroll 60 patients. Outcome measures will 
include patient reported outcomes: VAS, KOOS, Kujala, and IKDC. Additionally, we will report on rates of complications post -operatively, if any. Type I error rate (alpha) will be set at 0.05. Power will be set at 0.80.  
 
10 Source Documents and Access to Source Data/Documents  
 
Source data is all information, original records of clinical findings, observations, or other activities in a clinical 
trial necessary for the reconstruction and evaluation of the trial.  Source data are contained in source documents.  Examples of these original documents, and data records include: hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_110799], microfiches, photographic negatives, microfilm or magnetic media, x- rays, 
subject files, and records kept at the pharmacy, at the laboratories, and at medico- technical departments 
involved in the clinical trial. It is acceptable to use CRFs as source documents. If this is the case, it should be 
stated in this section what data will be collected on CRFs and what data will be collected from other sources.  
 The study case report form (CRF) is the primary data collection instrument for the study.  All data requested 
on the CRF must be recorded.  All missing data must be explained.  If a space on the CRF is left blank 
because the procedure was not done or the question was not asked, write “N/D”.  If the item is not applicable 
to the individual case, write “N/A”.  All entries should be printed legibly in black ink.  If any entry error has been made, to correct such an error, draw a single straight line through the incorrect entry and enter the correct data above it.  All such changes must be initialed and dated.  DO NOT ERASE OR WHITE OUT  
ERRORS.  For clarification of illegible or uncertain entries, print the clarification above the item, then initial 
and date it.  
 
Access to study records will be limited to IRB- approved members of the study team. The investigator will 
permit study -related monitoring, audits, and inspections by [CONTACT_1201]/EC, the sponsor, government regulatory 
bodies, and University compliance and quality assurance groups of all study related documents (e.g. source 
documents, regulatory documents, data collection instruments, study data etc.).  The investigator will ensure 
the capability for inspections of applicable study -related facilities (e.g. pharmacy, diagnostic laboratory, etc.).  
 Participation as an investigator in this study implies acceptance of potential inspection by  [CONTACT_28832].  
 
Study number:  s20-[ZIP_CODE]   Page 21 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_553748]: 11 January 2019  11 Quality Assurance and Quality Control  
 
QC procedures will be implemented beginning with the data entry system and data QC checks that will be run on the database will be generated. Any missing data or data anomalies will be communicated to the site(s) for 
clarification/resolution.  
 Following written SOPs, the monitors will verify that the clinical trial is conducted and data are generated, documented (recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).  
 
The investigational site will provide direct access to all trial related sites, source data/documents, and reports 
for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_3482].  
 
12 Ethics/Protection of Human Subjects  
12.[ADDRESS_727785]  
 The investigator will ensure that this study is conducted in full conformity with Regulations for the Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and/or the ICH E6. 
 
12.[ADDRESS_727786]  
 The protocol, informed consent form(s), and all participant materials will be submitted to the IRB for review and approval. Approval of both the protocol and the consent form must be obtained before any participant is enrolled. Any amendment to the protocol will require review and approval by [CONTACT_52590]. All changes to the consent form will be IRB approved; a determination will be made 
regarding whether previously consented participants need to be re- consented.  
12.3 Informed Consent Process  
12.3.1  Consent and Other Information al Documents Provided to Participants  
 Consent forms describing in detail the study agent, study procedures, and risks are given to the participant and written documentation of informed consent is required prior to starting intervention/administering study  
product. The following consent materials are submitted with this protocol: consent form, key information form.  
 
12.3.2  Consent Procedures and Documentation 
 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and 
continues throughout the individual’s study participation. Extensive discussion of risks and possible benefits of 
participation will be provided to the participants and their families  in a private office when they are being 
consented for their surgery . Consent forms will be IRB -approved and the participant will be asked to read and 
review the document. The investigator will explain the research study to the participant and answer any 
questions that may arise prior to their surgery . All participants will receive a verbal explanation in terms suited 
to their comprehension of the purposes, procedures, and potential risks of the study and of their rights as research participants. Participants will have the opportunity to carefully review the writ ten consent form and 
ask questions prior to signing. The participants should have the opportunity to discuss the study with their surrogates or think about it prior to agreeing to participate. The participant will sign the informed consent document prior t o any procedures being done specifically for the study. The participants may withdraw Commented [MR5]: Edit to state that subjects will be 
consented prior to the day of their surgery.  
Commented [EH6R5]: This has been amended  
Study number:  s20-[ZIP_CODE]   Page 22 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_553748]: [ADDRESS_727787]’s research record. The consent 
process, including the name [CONTACT_21811], will be thoroughly documented in the subject’s research record.  Any alteration to the standard consent process (e.g. use of a translator, consent 
document presented orally, etc.) and the justification for such alteration will likewise be documented.  
 
12.[ADDRESS_727788] of 1996 (HIPAA).  Those regulations require a signed subject authorization informing the subject  of the following:  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why  
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI.  
 In the event that a subject revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], retains the ability to use all information collected prior to the revocation of subject authorization.  For subjects that  
have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at 
least vital status (i.e. that the subject is alive) at the end of their scheduled study period.  
 
 Data will be de- identified with a unique code an d stored on password- protected computers behind the NYULH 
firewall as well as on REDCap, which is a HIPAA compliant and encrypted database managed by [CONTACT_553763].   
Data will only be available to the investigators.  The investigators will separately maintain the master list to 
reidentify subjects  using RedCap. 
 
12.[ADDRESS_727789] Keepi[INVESTIGATOR_007]  
13.1 Data Collection and Management Responsibilities 
 Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site PI. The 
investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data 
reported.  
 All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data. Black ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making changes or corrections, cross out the original entry with a single line, and initial and date the change. DO NOT ERASE, OVERWRITE, OR USE 
CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
 
Copi[INVESTIGATOR_58625] (eCRF) will be provided for use as source documents and maintained for recording data for each participant enrolled in the study. Data reported in the eCRF derived from source 
Study number:  s20-[ZIP_CODE]   Page 23 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_553748]: 11 January 2019  documents should be consistent with the source documents or the discrepancies should be explained and 
captured in a progress note and maintained in the participant’s official electronic study record.  
 Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical laboratory data will be entered into REDCap , a [ADDRESS_727790] protection and internal quality checks, such as 
automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the source documents.  
 
13.2 Study Records Retention  
 Study documents  will be ret ained for the longer of 3 years after close- out, 5 years after final 
reporting/publication, or [ADDRESS_727791] be reported to the local IRB per their guidelines. The site PI/study staff is 
responsible for knowing and adhering to their IRB requirements. Further details about the handling of protocol 
deviations will be included in the MOP.  
 
[ADDRESS_727792] with this study (patent ownership, royalties, or financial gain greater than the minimum allowable by [CONTACT_1385], etc.) must have the conflict reviewed by [CONTACT_33913] (CIMU) with a Committee- sanctioned conflict management 
Study number:  s20-[ZIP_CODE]   Page 24 
Version date: 8/4/2020    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in 
writing by [CONTACT_553748]: [ADDRESS_727793] policies.  
 